3,284 Shares in Illumina, Inc. (NASDAQ:ILMN) Purchased by APG Asset Management US Inc.

APG Asset Management US Inc. acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 3,284 shares of the life sciences company’s stock, valued at approximately $439,000.

Several other large investors have also bought and sold shares of ILMN. Golden State Wealth Management LLC purchased a new position in Illumina in the 4th quarter worth approximately $32,000. Versant Capital Management Inc grew its position in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 146 shares during the period. Bank Julius Baer & Co. Ltd Zurich bought a new position in Illumina in the 4th quarter worth $45,000. Assetmark Inc. boosted its holdings in Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after buying an additional 296 shares during the period. Finally, Lee Danner & Bass Inc. bought a new position in shares of Illumina during the 4th quarter valued at about $48,000. 89.42% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on ILMN. Piper Sandler increased their price objective on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Royal Bank of Canada lowered their target price on shares of Illumina from $128.00 to $112.00 and set an “outperform” rating for the company in a research note on Tuesday. Guggenheim dropped their price objective on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Citigroup cut their target price on shares of Illumina from $90.00 to $85.00 and set a “neutral” rating on the stock in a research report on Monday. Finally, Barclays restated an “underweight” rating on shares of Illumina in a report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $139.85.

Illumina Stock Performance

NASDAQ:ILMN opened at $76.30 on Thursday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The company has a fifty day moving average of $90.77 and a two-hundred day moving average of $123.08. The stock has a market capitalization of $12.09 billion, a PE ratio of -9.93, a P/E/G ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, research analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.